^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PF-08046044

    i
    Company:
    Pfizer
    Drug class:
    Topoisomerase I inhibitor, CD30-targeted antibody-drug conjugate
    Related drugs:
    23d
    SGN35C-001: A Safety Study of SGN-35C in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=170, Recruiting, Seagen Inc. | Trial completion date: Aug 2028 --> Apr 2029
    Trial completion date
    |
    PF-08046044
    11ms
    SGN35C-001: A Safety Study of SGN-35C in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=170, Recruiting, Seagen Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PF-08046044
    1year
    A Safety Study of SGN-35C in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=170, Not yet recruiting, Seagen Inc.
    New P1 trial
    |
    PF-08046044